Tech Center 1600 • Art Units: 1623 1626
This examiner grants 66% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18371085 | COMPOSITIONS FOR TREATING FUNGAL AND BACTERIAL BIOFILMS AND METHODS OF USING THE SAME | Non-Final OA | The Regents of the University of California |
| 17917445 | SMALL MOLECULE THERAPEUTICS FOR THE TREATMENT OF VIRAL INFECTIONS | Non-Final OA | The Regents of the University of California |
| 18266375 | DEGRADING PKCB1 TO TREAT CANCER | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18555344 | PESTICIDALLY ACTIVE CYCLIC AMINE COMPOUNDS | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18041572 | PROCESS FOR THE PREPARATION OF QUATERNIZED PYRIDAZINE DERIVATIVES | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 17799036 | METHOD FOR PRODUCING REDUCED COENZYME Q10 FORM II CRYSTALS | Final Rejection | KANEKA CORPORATION |
| 18462918 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Final Rejection | AbbVie Inc. |
| 18288314 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | Non-Final OA | Eli Lilly and Company |
| 18329895 | METHOD FOR INHIBITING METASTASIS OF TRIPLE-NEGATIVE BREAST CANCER USING ROSOXACIN | Non-Final OA | National Yang Ming Chiao Tung University |
| 18013302 | COMPOUNDS HAVING ANTICANCER ACTIVITY | Final Rejection | The Trustees of Princeton University |
| 18249435 | INHIBITION OF THE HIV-1 REPLICATION BY COMPOUNDS DIRECTED AGAINST A NEW TARGET OF THE VIRAL CYCLE | Final Rejection | UNIVERSITE PARIS-SACLAY |
| 18101340 | METHODS OF TREATING PSYCHIATRIC DISORDERS IN OBESE PATIENTS WITH BREXPIPRAZOLE | Non-Final OA | Lake O'Hara LLC |
| 17789115 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | Final Rejection | TYK Medicines, Inc. |
| 18030547 | SOLID STATE FORMS OF TRILACICLIB AND OF TRILACICLIB SALTS | Final Rejection | ASSIA CHEMICAL INDUSTRIES LTD. |
| 17998135 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Non-Final OA | Halia Therapeutics, Inc. |
| 17997422 | CORONAVIRUS INFECTION THERAPEUTIC AGENT FORMED THROUGH COMBINATION OF PYRAZINE DERIVATIVE AND ANOTHER CORONAVIRUS INFECTION THERAPEUTIC DRUG | Final Rejection | FUJIFILM TOYAMA CHEMICAL CO., LTD. |
| 18265131 | Method of Treating Viral Infection | Non-Final OA | Cipla Limited |
| 18546560 | TRPM8 AGONISTS AS COOLING AGENTS AND FOR THE TREATMENT OF DISEASE | Non-Final OA | Concentric Analgesics, Inc. |
| 18546312 | PYRROLO[3,2-D]PYRIMIDINE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | Non-Final OA | Tango Therapeutics, Inc. |
| 18276433 | AMIDE AND ETHER SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | Non-Final OA | TRIANA BIOMEDICINES, INC. |
| 18264079 | NOVEL PROCESS | Non-Final OA | ARTIOS PHARMA LIMITED |
| 18038258 | HETEROARYLQUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Non-Final OA | CHENGDU CYNOGEN BIO-PHARMACEUTICAL TECHNOLOGY CO., LTD. |
| 18037386 | ANTIVIRAL COMPOSITION FOR SARS-COV-2 AND HCOV-OC43 COMPRISING RHEIN, MECLOFENAMIC ACID, OR A COMBINATION THEREOF | Non-Final OA | INSTITUTE FOR BASIC SCIENCE |
| 18031679 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | Non-Final OA | Ranok Therapeutics (Hangzhou) Co. Ltd. |
| 18249728 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | Final Rejection | TME Therapeutics LLC |
| 18040708 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | Final Rejection | ITALFARMACO S.P.A. |
| 17191470 | Cannabis Treatment of Insomnia, Pain, and Skin Conditions | Final Rejection | Irvine Labs, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy